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Cotransplantation of neural progenitors (NPs) with Schwann cells (SCs) might be a way to overcome low
rate of neuronal differentiation of NPs following transplantation in spinal cord injury (SCI) and the improve-
ment of locomotor recovery. In this study, we initially generated NPs from human embryonic stem cells
(hESCs) and investigated their potential for neuronal differentiation and functional recovery when cocultured
with SCs in vitro and cotransplanted in a rat acute model of contused SCI. Cocultivation results revealed
that the presence of SCs provided a consistent status for hESC-NPs and recharged their neural differentiation
toward a predominantly neuronal fate. Following transplantation, a significant functional recovery was
observed in all engrafted groups (NPs, SCs, NPs + SCs) relative to the vehicle and control groups. We also
observed that animals receiving cotransplants established a better state as assessed with the BBB functional
test. Immunohistofluorescence evaluation 5 weeks after transplantation showed invigorated neuronal differ-
entiation and limited proliferation in the cotransplanted group when compared to the individual hESC-NP-
grafted group. These findings have demonstrated that the cotransplantation of SCs with hESC-NPs could
offer a synergistic effect, promoting neuronal differentiation and functional recovery.
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INTRODUCTION fibroblasts (58,81). A systematic review of cellular
transplantation therapies for spinal cord injuries (SCI)
in different animals from rodents to primates has beenThe limited endogenous capacity of the spinal cord
for repair and regeneration has directed the focus of pre- performed by Tetzlaff and colleagues (79). Accordingly,
neural stem cell or progenitor (NSC/NP) transplantationclinical trauma research toward ways for prevention of
cell death, cell transplantation, or support of degenerat- is one promising strategy for promoting functional
recovery from SCI by increasing survival and growth ofing neurons (8,80). A variety of cell replacement strate-
gies have been examined for the potential to repair and the host tissue, and/or replacement of lost cells primarily
due to their self-renewal and given their ability to gener-regenerate the spinal cord in animal models. The most
commonly used cell types include, but are not limited ate all types of neural cells (27,49). These cells are
derived from in vivo fetal/adult tissues (65) or pluripo-to, olfactory ensheathing cells (OECs) (43,72,75), bone
marrow and cord blood stromal cells (16,63,66), tent stem cells such as human embryonic stem cells
(hESCs) in vitro (20,24,34,37,45,76). hESCs provide aSchwann cells (SCs) (7,9,21), and genetically modified
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useful source of cells for basic developmental studies Merck) (17) on laminin (1 mg/ml) and poly-L-ornithine
(15 mg/ml, Sigma-Aldrich)-coated tissue culture dishesand cell-based therapies because of their unlimited self-
renewal and pluripotency capacities (31). So far, many in the same medium, which contained 20 ng/ml epider-
mal growth factor (EGF) and 20 ng/ml bFGF as NPpromising studies have shown the therapeutic potential
of hESC-derived NPs (hESC-NPs) to ameliorate neuro- expansion medium. Media were changed every other
day for 5–7 days. All experiments were performed bylogical diseases in animal models such as Parkinson’s
disease (5,73) and retinal macular degeneration (30,52). hESC-NPs at passage 11–15. Spontaneous differentia-
tion was performed in differentiation medium in theMoreover, grafting of ESCs into animal models with
SCI is shown to improve motor function (15,23,42,54). absence of growth factors, including: neurobasal
medium (Invitrogen)/DMEM-F12 (1:1), B27 (1%),However, there are two major problems with the use of
NP implants for the treatment of SCI: a poor survival knockout serum replacement (KOSR, 5%), and N2 sup-
plement (1%) for 35 days. Half of the medium wasrate and the low rate of differentiation of NPs into neu-
ronal cells (12,88). renewed every 5 days.
One way to overcome these problems is the cotrans-
plantation of cells, which has been tested to promote Immunocytofluorescence Staining
recovery in animal models of SCI (1,22,39,47,56,74, The cells were fixed in 4% paraformaldehyde or etha-84,91). To date, cotransplantation of NSCs with basic
nol for 20 min at room temperature and −20°C, respec-fibroblast growth factor (bFGF)-expressing amniotic
tively, permeabilized with 0.2% Triton X-100 for 5 min,
epithelial cells (56) and olfactory ensheathing cells
and blocked in 10% host (goat/rabbit) serum in PBS for(OECs) (84) has been reported. Additionally, a few stud- 1 h. Cells were incubated with primary antibodies (Tableies using in vivo-derived NPs and intact SCs or geneti- 1) for 1 h at 37°C, washed, and incubated with second-
cally modified SCs have induced functional recovery
ary antibodies (Table 1) as appropriate for 1 h at 37°C.
and achieved good neuronal differentiation of grafted The nuclei were counterstained with propidium iodide
cells in animal models of SCI (47,62,90,91), thus pro- (PI; Sigma, P4170) or 4,6-diamidino-2-phenylindole
viding mounting evidence for the idea that SCs may (DAPI; 1 µg/ml, Sigma-Aldrich, D-8417) and/or 1 µg/
contribute to survival and neuronal differentiation of
ml PI (Sigma-Aldrich, P4864) for 3 min at room temper-NPs in vivo.
ature. Omission of the primary antibody in the sampleIn the present study, initially we generated NPs from
was used as a control for all markers. Labeled cells werehESCs. hESC-NPs provide unlimited availability for
examined with a fluorescent microscope (Olympus,NPs and overcome teratoma formation, one of signifi- BX51, Japan) and images were acquired with an Olym-
cant hurdles in hESC technology. These NPs were then pus D70 camera.
cocultured with SCs isolated from rat sciatic nerve with
the intent to evaluate the effect of SCs on neurogenesis
Flow Cytometry Analysisin vitro. It was determined that SCs increased neuronal
differentiation of hESC-NPs in vitro. Then, to examine All staining reactions were performed in staining
buffer consisting of PBS supplemented with 1% fetalthe potential effect of SCs on promoting the in vivo neu-
ronal differentiation fate and functional recovery of bovine serum (FBS) and 0.085% EDTA (Sigma,
E6758). After determination of the cellular viability byhESC-NPs, we transplanted cultured SCs along with
NPs into contused injured spinal cords of adult rats. trypan blue exclusion, cells were washed twice in stain-
ing buffer and fixed in 4% paraformaldehyde or ethanol.
MATERIALS AND METHODS Triton X-100 (0.2%) was used for permeabiliztion. Non-
Culture of hESCs and Generation of NPs specific antibody binding was blocked with a combina-
tion of 10% heat-inactivated goat serum (SAFCThe hESC line Royan H6 (passage 45) (2) was used
in these experiments. Cells were expanded and passaged Biosciences, 12036-500M) in staining buffer and 1.5–
2.0 × 105 cells were used per sample. Cells were incu-under feeder-free culture conditions in hESC medium
that contained 100 ng/ml bFGF as previously described bated with the appropriate primary antibodies or
appropriate isotype-matched controls. Primary antibod-(57). The medium was changed every other day, until
day 7. To generate NPs from feeder-free hESCs, we ies used were: anti-nestin, anti-Sox1 (sex determining
region Y-box containing gene 1), and anti-p75 low-employed a protocol that used a combination of retinoic
acid (RA; 2 µM, Sigma-Aldrich), bFGF (100 ng/ml, affinity nerve growth factor receptor (P75LNGFr)
(Table 1). The cells were washed two times in stainingRoyan institute), and noggin (250 ng/ml, R&D) in
DMEM-F12 medium as previously described (59). buffer and incubated for 30 min at 4°C with the appro-
priate secondary antibody (Table 1). After washing, flowThe hESC-NPs were passaged using 0.008% trypsin
(Invitrogen)/2 mM ethylenediaminetetraacetic acid (EDTA; cytometric analysis was performed with a BD-FACS
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Table 1. Antibodies Used in This Study
Target Phenotypes: Primary Abs Antibody Host Vender Cat. No. Dilution
Human identity HNRNPAO (human nuclear antigen) rabbit Abcam ab66661 6 mg/ml
Neuronal precursor Nestin mouse Chemicon Mab5326 1:200
Neuronal precursor Sox1 rabbit Abcam Ab22572 1:1000
Neuronal precursor Pax6 (H-295) rabbit Santa Cruz C-11357 1:200
Oligodendrocyte MBP (myelin basic protein) mouse Abcam ab22460 1:1000
Neuron—early TUJ1 (β-III-tubulin) mouse Sigma T8876 1:200
Neuron—early TUJ1 (β-III-tubulin) rabbit Sigma T3952 1:200
Neuron—mature MAP-2 (microtubule associated protein-2) mouse Lifespan LS-C8665 0.5 mg/ml
Mitotic marker Ki67 mmouse Chemicon MAB4190 1:200
Astrocyte GFAP (glial fibrillary acidic protein) mouse Abcam Ab8975 1:200
Schwann cell P75LNGFr mouse Abcam ab6172 1:500
Secondary Abs: Conjugated With Antibody Vender Cat. No. Isotype Dilution
FITC goat anti-mouse Chemicom AP124F IgG 1:50
FITC goat anti-rabbit Sigma F1262 IgG 1:50
TRITC goat anti-mouse Sigma T7782 IgG 1:50
FITC goat anti-mouse Sigma F9259 IgM 1:80
Sox1, sex determining region Y-box 1; Pax6, paired box gene 6 (aniridia, keratitis); P75LNGFr, p75 low-affinity nerve growth factor receptor;
FITC, fluorescein isothiocyanate; TRITC, tetramethyl rhodamine isothiocyanate.
Calibur Flow Cytometer. The experiments were repli- a2), Hoxa5, Hoxb4, and Hoxc5 were designed with Perl-
primer V.1.1.14 software. Real-time RT-PCR was car-cated three times and the acquired data were analyzed
with WinMDI (2.9) software. ried out using a 96-well optical reaction plate and a 7500
real-time PCR system (Applied Biosystems). For each
PCR run, 40 ng cDNA products were mixed with 1×Karyotype Analysis
SYBR Green PCR Master Mix and PCR primers in aKaryotype analysis was done as described elsewhere
total volume of 20 µl. Relative gene expression was ana-(57). Briefly, the cells were treated with thymidin (0.66 lyzed using the comparative Ct method, 2−∆∆Ct (50). Tar-µM, Sigma) for 16 h and then with colcemid (Gibco, 0.15 get genes were normalized by the reference gene, β-actinµg/ml, 30 min). Subsequently, the cells were exposed to (31), and calibrated for each sample against control cells0.075 M KCl at 37°C for 16 min and fixed three times (undifferentiated hESCs). Each experiment included
with ice-cold 3:1 methanol/glacial acetic acid and
three replicates and each replicate consisted of two iden-dropped onto precleaned chilled slides. Chromosomes
tical samples. Thermal conditions for all genes were the
were visualized using standard G-band staining. At least
same and the annealing temperature was 60°C.20 metaphase spreads were screened and 10 of them were
evaluated for chromosomal rearrangements. Animals
Subjects of this study were Wistar rats (Pasteur Insti-
RNA Isolation and Real-Time RT-PCR for Gene tute, Tehran, Iran) weighing about 250–300 g. All ani-
Expression Analysis mal care, surgical processes, and postoperative euthanasia
were undertaken in strict accordance with the approvalThe expression patterns of specific genes were stud-
ied and compared with undifferentiated hESCs. From of the Institutional Review Board and Institutional Ethi-
cal Committee. All efforts were made to minimize theeach sample, total RNA was extracted using RNX
reagent (Cinnagen, RN7713C). RNA (5 µg) was treated number of animals used. Animals were housed two per
cage and provided free access to food and waterwith DnaseI (Fermentas). cDNA was synthesized from
1 µg of RNA using the RevertAidTM H Minus First throughout the study. All surgical procedures were per-
formed under anesthesia produced by a combination ofStrand cDNA Synthesis Kit (Fermentas) with a random
hexamer primer. The resulting cDNA were subjected to ketamine (100 mg/kg) and xylazine (10 mg/kg) (61).
real-time RT-PCR. Specific human primers Oct4
Isolation, Culturing, and Labeling of SCs[octamer binding protein 4; POU domain, class 5, tran-
scription factor 1(Pou5F1)], Nanog (Nanog homeobox), SCs were isolated from adult rats’ sciatic nerve bilat-
eral biopsies according to established protocols (60). InOtx2 (orthodenticle homeobox 2), Hoxa2 (homeobox
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brief, 2 weeks after in vitro predegeneration, sciatic and washed three times in PBS. A sample of the resulting
single cell suspensions was stained with trypan blue dyeexplants were dissociated and plated onto 2 µg/ml lami-
nin-coated dishes in DMEM medium. Finally, the exclusion (Sigma) and counted with a Neubauer hemocy-
tometer. hESC-NP and SC suspensions were mixed andmedium was changed with melanocyte growth medium
(MGM, PromoCell, C-24300) to which 2 µM forskolin diluted in PBS to yield the appropriate cell densities for
the various grafting paradigms.(Calbiochem, 344273), 10 ng/ml FGF2 (Sigma, F0291),
and 5 µg/ml bovine pituitary extract (BPE-26, Promo-
cell, C-30021) were added in order to prevent fibroblast Surgical Procedure, Experimental Grouping,
and Transplantationproliferation. Ethylene glycol tetraacetic acid (EGTA)
purification was implemented after 5–6 days and the
SCI Model. Prior to any surgical manipulation, allsupernatant was collected and transferred to new dishes.
animals were trained for the Basso Beattie BresnahanThe purity of SCs for grafting was greater than 99%. (BBB) test (see below) for 4 days with two repeatedLater passages (passages 3–4) were used in the cocul-
trials per day. Weight-drop contusion injury was carriedture system.
out according to Gruner (29) and Widenfalk et al. (86).PKH fluorescent dye was used to label SCs before
Briefly, following an incision through the skin, subcutis,transplantation. According to its protocol, adherent SCs
and muscle, a T9-10 laminectomy was performed. Next,were suspended in a 2× suspension of the respective
the vertebral column was stabilized by clamps attachedcells and a 2× dye solution, both in the PKH diluent
to the spinal processes, cranial and caudal to the lami-supplied with the kit (PKH26-GL, Sigma), mixed, and
nectomy. For the contusion injury a 10-g rod was raisedincubated for 3 min. The labeling reaction was stopped
to a height of 25 mm above the dorsal surface of theby addition of medium plus 10% serum. Labeled SCs
spinal cord. It was then released and accelerated by thewere washed three times to remove unbound dye. The
force of gravity until it hit the exposed spinal cord.stable partitioning of the fluorescent dye into the mem-
Afterwards, the surgical wounds were sutured, and thebrane permits long-term monitoring while leaving the
animals were given postoperative analgesia and Ringer’simportant functional surface proteins unaltered. The
solution (5 ml, SC) to prevent dehydration. Animalslabeled SCs (passages 3–4) were transplanted into con-
were allowed to recover and were housed in standardtusion models of SCI.
rat cages at a temperature of 27°C. Their bladders were
manually expressed three times daily until return ofCoculture of hESC-NPs and SCs
reflexive bladder control.For coculture, approximately 3 × 104 hESC-NPs were
added onto the SCs. In the control group, hESC-NPs Experimental Grouping and Transplantation. Forty-
eight rats with normal locomotor performance werewere seeded onto poly-L-ornithine (15 µg/ml, Sigma,
P4957) and laminin (15 µg/ml, Sigma, L2020)-coated selected. The sham group (n = 8) had only laminectomy
whereas rats in the other group were subjected to SCI.coverslips in expansion medium for 24 h to improve
attachment and allow for a consistent cell status. Subse- Rats with mean BBB scores of 1, indicating slight
movement of one or two joints, were randomly assignedquently, the medium was switched to differentiation
medium consisting of a mixture of DMEM/F12 neuroba- into five groups 1 week after SCI. The injury control
group (n = 8) received no manipulations. The vehiclesal medium (1:1) with 5% KOSR, 1% N2, 1% B27, 2
mM L-glutamine, 1% nonessential amino acids, 100 transplanted group (n = 8) received 5 µl PBS in the epi-
center of the contusion. hESC-NP transplantation (n =U&/ml penicillin, and 100 µg/ml streptomycin. Half of
the medium was changed every 3–4 days and continued 8) and SC transplantation groups (n = 8) each received
0.5 × 106 hESC-NP and SC suspensions in 5 µl PBS,for 3 weeks. Next, fixation and immunostaining were
implemented for the TUJ1 (β-III-tubulin antibody), respectively. The hESC-NP/SC cotransplantation group
(n = 8) received 0.5 × 106 of each of the aforementionedMAP2 (microtubule associated protein 2), and GFAP
(glial fibrillary acidic protein) markers. cells or, in total, 1 million cells in 5 µl PBS. The viabil-
ity of cells before transplantation was more that 97% by
Preparation of Cells for Transplantation trypan blue exclusion dye assay.
For cell transplantation into the spinal cord lesions aFor identification after transplantation, we utilized
human nuclear antigen (HNu). HNu is a selective nuclear 25 µl Hamilton syringe connected to a 27-gauge needle
through a glass capillary (inner diameter 50 µm) wasmarker of cells originating from humans. Therefore, it
was not necessary to label hESC-NPs. SCs were prela- used. A Kopf microstereotaxic injection system (David
Kopf Instruments) infused the suspension at a rate of 0.5beled with PKH-26 (PKH26-GL, Sigma), which allowed
for the identification of grafted cells in vivo. Immediately µl/min. After grafting, the syringe was raised 1 mm and
left in place for 5 min to minimize cell diffusion up thebefore transplantation the respective cells were harvested
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needle track. Animals were given gentamycin (15 mg/ PBS and counterstained with DAPI. The coverslips were
mounted onto glass slides with Entellan (Merck, Germany).kg, SC) and Ringer’s solution (5 ml, SC), and kept on a
heating pad until they woke. Animals were then housed For quantitative determination of the differentiation pat-
tern of transplanted cells, a fluorescence microscopein standard rat cages at a temperature of 27°C. Starting
2 days before transplantation, all groups of rats received (Olympus BX51, Japan) equipped with an Olympus
DP70 camera was used to evaluate the number of HNu/daily injections of cyclosporine A (10 mg/kg, SC, San-
dimmune, Novartis Pharmaceuticals, East Hanover, NJ, DAPI-positive cells. For each cell marker, we used three
to five tissue sections per rat (at 50 µm apart) from fourUSA) to prevent rejection.
rats. Then we counted the number of HNu/DAPI-posi-
Behavioral Assessment tive cells that were double-labeled cells with the cell
marker in 10 random fields per section. On average,To compare the functional outcome of various treat-
ments over time, gait abnormalities in rats were blindly 100–200 cells were counted per section.
evaluated by two observers using the BBB Locomotor
Statistical AnalysisRating Scale (3). Rats were placed in an open field (75 ×
All data are expressed as mean ± SEM. A value of125 cm) and observed for 4 min. Hind limb function
p < 0.05 was considered statistically significant. BBBwas scored from 0 to 21 (flaccid paralysis to normal
scores were compared using one-way ANOVA analysisgait). Performance in behavioral task was performed 3
followed by Tukey’s post hoc test for multiple compari-days before injury, prior to transplantation, and continu-
sons. The Student’s t-test was performed to determineously, once weekly, for a further 5 weeks after trans-
statistical differences between immunostaining in hESC-plantation.
NP and hESC-NP/SC cocultures and transplantation. All
Sacrifice and Cryosection statistical analyses were performed on standard statistics
computer software (SPSS 11.5 for Windows).After the behavioral analysis, all rats were given a
single dosage of anesthesia, a combination of ketamine RESULTS(100 mg/kg) and xylazine (10 mg/kg), and then trans-
Generation and Growth of hESC-NPscardial perfusion of anesthesia, with 0.1 M cold PBS
followed by 400 ml of ice-cold 4% paraformaldehyde Feeder-free cultured hESCs were induced to produce
neural rosettes, a distinct cluster of columnar cells, andin PBS (pH 7.4). Rat spinal cords were dissected and
postfixed at 4°C, then cryoprotected with 30% phos- then manually harvested under phase contrast micros-
copy. Next, hESCs were dissociated into single cells andphate-buffered sucrose at 4°C for 96 h. Samples were
successively cryosectioned in a longitudinal manner and plated in fresh defined medium in the presence of bFGF/
EGF on a laminin/poly-L-ornithine substrate. Culturesfrozen for further processing. Slice thickness was 10 µm
and they were sampled at every five section intervals. were subsequently passaged at a high cell density (1:2
ratio) every 5–7 days. These conditions generated a pop-
Immunohistofluorescence Staining and Quantification ulation with homogeneous morphology that formed mul-
tiple foci of rosette-like structures throughout the cultureFor dual immunohistofluorescence staining, sections
were rehydrated in 0.1 M PBS and permeabilized with (Fig. 1A). The hESC-NP cultures stained uniformly for
nestin (Fig. 1B) and Sox1 (Fig. 1C). Flow cytometry0.1% Triton X-100 (except for membranous markers) in
PBS. After blocking nonspecific sites with 10% normal analysis revealed that 84.5 ± 4.5% and 79.0 ± 3.7% of
the cells were positive for nestin (Fig. 1D) and Sox1serum and 1 mg/ml bovine serum albumin (BSA), sec-
tions were incubated for 2 h with primary antibodies (Fig. 1E), respectively. Under our culture conditions,
G-band karyotyping of these hESC-NPs confirmed awhich addressed human (graft) versus rat (host) cell
identity, mitotic activity, and neuron, astrocyte, and normal karyotype after 11 passages (Fig. 1F). Few
hESC-NPs expressed neuronal markers such as MAP2oligodendrocyte phenotype specifications. Antibodies
implemented for immunohistofluorescence are presented (Fig. 1G) and β-III-tubulin (TUJ1 staining; Fig. 1H), and
the astroglial marker, GFAP (Fig. 1I).in Table 1.For survival studies and tracing of cell fates,
we utilized HNu raised in rabbits whereas the remaining To assess the regional fate determination of hESC-
NPs during rostrocaudal axis, the expression of region-primary antibodies were raised in mice. Normal IgG
from the species of origin of the primary antibodies specific transcription factors in hESC-NPs cultured for
passage 20 was studied by qRT-PCR (Fig. 1J). Theserved as negative controls. After washing with PBS,
cells were incubated with the appropriate fluorescein expression of pluripotent stemness markers, Oct4 and
Nanog, and forebrain-rostral midbrain marker, Otx2,isothiocyanate (FITC) and tetramethyl rhodamine iso-
thiocyanate (TRITC) conjugated secondary antibodies were downregulated. However, the expression of Hoxa2,
Hoxa5, and Hoxb4, hindbrain markers, was upregulated,for 1 h at 37°C. Sections were washed three times with
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and Hoxc5, a cervical spinal cord marker was not marker was lower in coculture when compared to the
control (19 ± 1.7% vs. 32.0 ± 1.8%, p < 0.01, Student’schanged. Therefore, it seems that the generated hESC-
NPs are related to hindbrain. t-test) (Fig. 3H). Together these data suggest that hESC-
NPs differentiated preferentially to neuronal cells whenWe evaluated the potency of hESC-NPs to spontane-
ously undergo neural lineage differentiation by with- cocultured on SCs.
drawal of growth factors in differentiation (Fig. 1K).
Functional RecoveryImmunofluorescence staining showed that our NPs
could differentiate into neurons and glia (Fig. 1L–N). Since the neuronal differentiation effect of SCs on
NPs in vitro was seen, we hypothesized that cotransplan-
Culture of SCs tation of SCs with hESC-NPs could improve the func-
tional recovery in contusion-injured spinal cords of ratsSCs were isolated from adult sciatic nerve biopsies
according to our established protocol, as described pre- by increasing neuronal differentiation in vivo. Using a
dissecting microscope, a laminectomy was made at theviously (60). SCs at passages 3–4 were used in this
study. Purity of cells was above 99% as determined by T9-T10 spinal vertebrae, followed by a contusion injury
at the T10 level in which a 10-g rod was dropped uponflow cytometry. The viability after labeling with trypan
blue showed more than 97% vitality of PKH-26-labeled exposed vertebra. Figure 4A, B shows the spinal column
before and after contusion. Hematoxylin and eosincells. To evaluate whether or not permeabilization could
fade away the membranous PKH-26 labeling, immuno- (H&E) staining of coronal sections showed distinct
interruption of myelin homogeneity and cavity forma-staining for GFAP, a cytoplasm marker to assess SCs,
was used (64). The results revealed that PKH had a sta- tion that is usually observed in the contusion-injured spi-
nal cord of rats (3) or primates (36) (Fig. 4C, D).ble attachment in the membrane and did not clean off
through permeabilization with Triton X-100 from SCs The timing of SCI, cyclosporine administration, and
cell transplantation are outlined in Figure 4E. To evalu-(Fig. 2).
ate the effect and fate of hESC-NPs and rat SCs in the
Coculture of hESC-NPs and SCs SCI model, we transplanted the cells subacutely into the
rat contused spinal cord (Fig. 4E). To determine loco-To surmise the possible effects on SCs, NPs were
cocultured with rat SCs in neural differentiation medium motor recovery, BBB scoring of the open-field walking
test was performed before the contusion and up to 6for 3 weeks (Fig. 3A). The adhesion of hESC-NPs in
the coculture group was higher than the absence of SCs. weeks later (Fig. 4F). After SCI, animals displayed com-
plete and flaccid paralysis of both hind limbs. To ensureAdditionally, hESC-NPs formed a network with small
windows when cocultured with SCs, and SCs were that initial BBB scores were uniform between groups,
BBB was tested at day 6 (1 day prior to transplantation).observed mainly within the windows of this network
(Fig. 3B–D). Moreover, interestingly, neurons extended Rats with mean BBB scores of 1 were randomly
included in our experimental groups. Open-field loco-out longer processes when cultivated with SCs (Fig.
3D). Immunofluorescence staining of spontaneous dif- motion in the cell transplanted groups (hESC-NPs,
hESC-NPs/SCs, and SCs) was significantly improved upferentiated hESC-NPs in the presence and absence of
SCs revealed that cocultured hESC-NPs expressed neu- to 5 weeks postimplantation compared to the vehicle and
control groups (p < 0.01, one-way ANOVA, post hocronal markers to a significantly higher degree than those
grown without SCs (TUJ1 staining: 74.8 ± 1.4 vs. 50.0 ± Tukey’s test). Animals in the hESC-NP and SC groups
showed a similar recovery for 3 weeks after transplanta-0.9, p < 0.01; MAP2: 68.3 ± 1.8 vs. 45.4 ± 1.4, p < 0.01,
Student’s t-test) (Fig. 3E–H). The percentage of GFAP tion. Afterwards, and by the end of the study, the BBB
FACING PAGE
Figure 1. The characterization of human embryonic stem cell-derived neural progenitors (hESC-NPs). Phase contrast photomicro-
graph of confluent hESC-NPs as a monolayer at passage 11 (A). Immunofluorescence staining indicated that the established hESC-
NPs expressed nestin (B) and sex determining region Y-box1 (Sox1) (C). Flow cytometry analysis of hESC-NPs for the related
markers (D, E). Cytogenetic evaluation of the hESC-NP line at passage 11 by standard G-banding (F). A few cells expressed
neuronal microtubule associated protein 2 (MAP-2) (G) and β-III-tubulin (shown by Tuj1 staining) (H), and astroglial markers,
glial fibrillary acidic protein (GFAP) (I). Quantitative real-time RT-PCR of hESC-NPs, relative to undifferentiated hESCs. The
mean of each triplicate is plotted and error bars represent standard error (J). Growth factor removal from culture medium at passage
11 gave rise to spontaneous differentiation after 35 days. Phase contrast photomicrograph (K) and immunofluorescence staining for
β-III-tubulin (TUJ1) (L), MAP2 (M), and GFAP markers (N). Scale bars: 200 µm (B, H, I), 100 µm (G). DAPI, 4′,6-diamidino-2-
phenylindole; Otx2, orthodenticle homeobox 2; Hoxa2, homeobox a2; OCT3/4, octamer binding protein 3/4; PI, propidium iodide.
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Figure 2. Isolated Schwann cells (SCs) in vitro. Phase-contrast micrograph of SCs (A). Immunostaining for p75 low-affinity nerve
growth factor receptor (P75LNGFr) (B) and at higher magnification (C). Flow cytometry histogram for P75LNGFr (D). SC suspen-
sion immediately after labeling with PKH-26 (the red fluorescent cell membrane linker) labeled cells acquire a punctuate and/or
patchy appearance (E), and 1 day after plating (F). Immunostaining of PKH labeled SCs for GFAP as a marker for glial cells
(G–I). The stable attachment of the fluorescent dye into the membrane does not clean off through permeabilization with Triton X-
100. Scale bars: 100 µm (A), 200 µm (B), 50 µm (C), 200 µm (E–I).
score of hESC-NPs increased (p < 0.05, one-way ANOVA, We found that a larger percentage of animals had
higher BBB scores in the hESC-NP/SC group comparedpost hoc Tukey’s test), while recovery of SC trans-
planted animals remained unchanged. At the fifth week to the hESC-NP or SC groups. For example, 50% of the
rats that received hESC-NPs/SCs scored 14 compared toposttransplantation, the highest functional recovery was
observed in the hESC-NP/SC transplanted group in the hESC-NP or SC groups whose scores were less 5
weeks after transplantation (Fig. 4G).comparison with the hESC-NP or SC transplanted
groups (at least p < 0.05, one-way ANOVA, post hoc
Fate of Transplanted CellsTukey’s test). The hESC-NP/SC group achieved a mean
BBB score of 13.1 ± 0.4. In contrast, the hESC-NP or Animals were sacrificed after 5 weeks and immuno-
cytochemistry was carried out on the cords to elucidateSC transplanted groups only achieved mean BBB scores
of 10.8 ± 0.3 and 8.5 ± 0.2, respectively. The BBB the possible mechanisms that led to the observed func-
tional recovery. The survival of transplanted hESC-NPsscores in hESC-NP or SC transplanted groups were sig-
nificantly more in the vehicle (6.0 ± 0.3) and control and SCs was assessed using PKH labeling and a selec-
tive marker of human cell (HNu) immunostaining,groups (5.5 ± 0.2) (p < 0.01, one-way ANOVA, post hoc
Tukey’s test) (Fig. 4F). respectively. Examination of the sections revealed that
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SCs were generally observed in the lesion cavity, HNu- percentage of cells expressing the respective markers,
the numbers of HNu-positive cells were divided to theirpositive cells were clearly visible around the lesion
perimeter and migrated rostrocaudally to the surround- respective markers. The results disclosed that by the end
of the fifth week of transplantation 12.3 ± 0.75%, 4.6 ±ing gray and white matter (mainly caudal) (Fig. 5A, B).
Sciatic nerve purified SCs expressed P75LNGFr marker, 0.25%, 15.3 ± 1.7%, and 31.1 ± 0.73% of cells were
positive for TUJ1 staining, MAP2, myelin basic proteina specific cell surface maker. Examination of sections
confirmed its expression on labeled SCs (Figs. 5E–H). (MBP), and GFAP, respectively. Additionally, about
one third of the engrafted cells (33.0 ± 0.77%) were nes-Moreover, the presence of P75LNGFr-positive cells that
were not PKH labeled or HNu positive, which indicated tin immunoreactive, which suggested that they remained
largely undifferentiated. The presence of SCs in thenative migratory SCs to the injured spinal cord, was
noted (6) (Fig. 5E–H). To determine the phenotype of hESC-NP/SC transplanted group was able to signifi-
cantly boost the proportion of neuronal markers whenHNu-positive cells, dual-label immunofluorescence was
performed for neuronal, astroglial, oligodendroglial, compared with hESC-NP transplanted group (TUJ1
staining: 20.2 ± 0.5 in hESC-NPs/SCs vs. 12.3 ± 0.7 inmitotic, and progenitorial markers. To determine the
Figure 3. Coculture of hESC-NPs and SCs. Schematic coculture illustration. Briefly, hESC-NPs were added on SCs. After 1 day,
medium was switched into differentiation medium and continued for 3 weeks (A). Phase contrast photomicrograph of cocultivated
NPs and SCs (B), and higher magnification in (C, D). Note the long processes that occur more often in a cocultivated system (D).
Double immunostaining of cocultured hESC-NPs for HNu and β-III-tubulin (TUJ1) (E), or MAP2 (F) and/or GFAP (G). Quantita-
tive immunofluorescence staining showed a significant increase in neuronal markers and decrease in GFAP expression in cocultured
NPs in comparison with spontaneous differentiation of only hESC-NPs (H). The Student’s t-test was used to compare immunostain-
ing data between hESC-NP and hESC-NP/SC groups. a: p < 0.01. Scale bars: 200 µm (B), 100 µm (C, D), 200 µm (E–G).
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Figure 4. Injury, cell transplantation protocol, and Basso Beattie Bresnahan (BBB) score. Exposed spinal cord and surrounding
meninges before contusion (A). Spinal cord after spinal cord injury (SCI); note the hemorrhage at the lesion spot (white arrow)
(B). H&E-stained photomicrograph of lesion site representative of disintegration and interruption of spinal tissue (C). A section
crossing the central canal of the contused spinal cord (black arrows) (D). Schematic illustration outlining in vivo procedure compris-
ing study period, the time of injury, transplantation, cyclosporine administration (E). Hindlimb locomotor function assessment by
BBB gait scale. TX indicates the time of transplantation. BBB score of hESC-NP/SC transplanted rats were significantly higher
than control, vehicle, and individual cell grafts (F). Except for the first week after transplantation in which SC-transplanted animals
displayed a better functional outcome, a larger proportion of hESC-NP/SC transplanted animals had a higher BBB score beginning
from the second week until the study ended (G). We performed one-way ANOVA analysis followed by Tukey’s post hoc test for
multiple comparisons. n = 8 per group. a: p < 0.01, hESC-NP/SC group versus SC group; b: p < 0.01, hESC-NP group versus
vehicle and control groups; c: p < 0.01, hESC-NP/SC group versus vehicle and control groups; d: p < 0.05, hESC-NP/SC group
versus hESC-NP group; e: p < 0.05, hESC-NP group versus SC group; f: p < 0.05, SC group versus vehicle and control groups.
Scale bars: 200 µm (C, D).
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Figure 5. Tracing of transplanted cells in longitudinal sections of spinal cords. Low magnified (10×) image for transplanted hESC-
NPs using human nuclei (HNu) antibody, 5 weeks after transplantation. hESC-NPs were mostly observed around the lesion cavity
intermingled between spared white and gray matter. A few numbers of hESC-NPs were detected up to 8 mm away from the injury
epicenter. The asterisk indicates lesion cavity (A). Higher magnification of boxed area in A (B). SCs survived and remained in the
grafting site 5 weeks after transplantation (C). Longitudinal section of hESC-NP/SC transplanted spinal cord. PKH-26 indicates
SCs mostly resided at the grafted area. HNu-positive staining indicates the extent of hESC-NPs that survived and migrated out of
the lesion cavity and dispersed in a rostrocaudal direction (D). Microphotograph of PKH-26-labeled SCs for rat P75LNGFr demon-
strates its expression on the plasmalemma of SCs (E–H). Moreover, the presence of PKH-26− and P75LNGFr+ cells indicates
endogenous SC recruitment into the injured spinal cord. Scale bars: 2 mm (A), 1 mm (B–D), 200 µm (E–H).
hESC-NPs; MAP2: 12.0 ± 0.6 in hESC-NPs/SCs vs. 4.6 ± DISCUSSION
0.2 in hESC-NPs, p < 0.01, Student’s t-test) (Fig. 6).
Furthermore, expression of nestin, a neural progenitor Here we have shown SC transplantation 7 days after
contusive injury at the 10th thoracic vertebral (T10)marker, was significantly reduced compared to the
hESC-NP transplanted group (25.0 ± 0.6%.0 in hESC- level resulted in significant locomotor functional recov-
ery compared to the control and vehicle groups. SCsNPs/SCs vs. 33.0 ± 0.7% in hESC-NPs, p < 0.01, Stu-
dent’s t-test) (Fig. 6). However, there was no significant have been used following SCI, and it is known that SCs
promote axonal regeneration and myelination after SCIdifference in both transplanted groups for GFAP and
MBP (GFAP: 29.4 ± 0.6 in hESC-NPs/SCs vs. 31.0 ± (7,9,21). By this way, there was a significant reduction
in cyst formation, increased tissue sparing, support of0.7 in hESC-NPs, MBP: 17.0 ± 1.0 in hESC-NPs/SCs
vs. 15.3 ± 1.2 in hESC-NPs) (Fig. 6). These results sug- axonal growth into the graft, significant improvement in
axon sparing and/or growth of spinal and supraspinalgested that cotransplantation led to differentiation of
hESC-NPs into more mature neurons compared to the axons, and modest improvement in locomotor function
(78). These improvements can be attributed to theirhESC-NP group.
Moreover, 4.0 ± 0.9% (in hESC-NP/SC group) and membranes, extracellular matrix, and their production of
diffusible trophic factors [for review see (87)]. More-4.6 ± 0.6% (in hESC-NP group) of the transplanted
cells expressed Ki67, a cell cycle marker (Fig. 6). over, PKH labeling of the SCs has shown that the major-
ity of the SCs remained in the grafted area, in accordanceKi67-positive cells were found randomly dispersed
across the graft area without evidence of clustering in with previous studies (6,69,78). Modification of SCs to
release neurotrophic factors (28,55) or the combinationspecific sites. There were no considerable differences
in Ki67-positive cells between the cotransplant and of SCs with other alternatives such as cAMP (69), OECs
(68), and chondroitinase (26) may to a certain degreehESC-NP groups (Fig. 6). No evidence of tumor for-
mation was observed in the transplantation groups. fulfill the endeavor appointed to SCs.
On the other hand, there are several reports that showTherefore, although teratomas are predominantly
derived from the hESC graft, the purified hESC- transplantation of NPs or NSCs provides a promising
future to improve functional recovery in the SCI ratderived differentiated cells provide an opportunity for
cell-based therapies. model [for review see (79)]. NPs have been isolated
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from numerous regions in the developing and adult ner- mechanism (25,35,38,48,71,77). The possibility that
hESC-NPs affect host locomotor recovery by means ofvous system (19,89). Here, we have shown that NPs can
generate in large quantities of enriched stable proliferat- multiple mechanisms such as increasing host neuronal,
oligodendroglial, or axonal survival or decreasing hosting cells from hESCs using an adherent system and
defined medium supplemented with a combination of glial scaring, and increasing host-mediated regeneration
or remyelination must also be considered.inducing and growth factors. The differentiated cells
highly expressed nestin and Sox1, molecular features of To improve the neuronal and oligodendrocyte differ-
entiation from transplanted hESC-NPs and generation ofNPs, and had the caudal region identity. Our hESC-NPs
have the capability of continuous self-renewal and nor- a proper microenvironment for treatment of acute SCI,
here we have applied the cotransplantation of hESC-NPsmal karyotype in the presence of EGF and bFGF. They
are also multipotent, as they give rise to neurons and with SCs. By this way, hESC-NPs leave the cavity into
the spared tissue and emigrated both rostrocaudally.glia after growth factor removal. The characteristics of
our generated hESC-NPs provide the opportunity to Moreover, immunostaining showed approximately twice
the increment of TUJ1- and MAP2-positive cell forma-exploit ready-to-use hESC-NPs for future biomedical
applications. Recent studies have generated efficient tion compared to individual hESC-NP grafting 5 weeks
after transplantation. Therefore, neuronal differentiationNPs from hESCs that have self-renewal potential from
rosette-forming cells isolated during early hESC differ- of hESC-NPs after cotransplantation into the lesioned
spinal cord has been improved when compared with NPentiation stages (20,24,34,37,45,76).
There are limited data available on the transplantation transplantation alone, in which fewer NPs differentiate
into neuronal cells (13). This finding is of importanceof ESC-NPs in SCI (44,46) or severe sciatic nerve axo-
tomy in rats (18). Recently, we have demonstrated that given that cotransplantation of SCs enhances more NP
differentiation into neuronal cells. It seems that thesetransplantation of hESC-derived neural tube-like struc-
tures, including primary NPs with the differentiation promoting effects of the cotransplantation on hESC-NPs
can be attributed to the properties of SCs, which havepotential of neuronal and glial cells in collagen gels,
improves functional recovery of SCI in adult rats sub- been previously discussed. Another aspect is that SC
cotransplantation may drive the transplanted hESC-NPsjected to midline lateral hemisection SCI (31). There-
fore, in the present study we evaluated the therapeutic to serve a more trophic role and alter the host microenvi-
ronment. Moreover, there is evidence that neurotrophinseffects of transplanting self-renewable hESC-NPs on the
functional recovery on a rat SCI contusion model. Inter- released by SCs could upregulate TrkC-mediated neu-
ronal differentiation of NPs (11,14,92). The possibilityestingly, we found that transplantation of hESC-NPs
improved significant locomotor functional recovery after of SCs in breaking down the myelin debris (83) and
myelination prosperities could be another possibility inSCI. This improvement was higher in hESC-NPs com-
pared to SCs and exhibited neurogenic and gliogenic aforementioned recovery and suggest more specific
evaluation on myelin characterization by electron micros-differentiation, which was similar to those seen in vitro.
Moreover, the hESC-NPs in this study expressed MBP, copy (6,41). Alternatively, the mechanisms mediating
recovery of function may be cell population interactionwhich represented myelin-forming potential. Therefore,
we hypothesize that our hESC-NPs were differentiated specific. Further studies are needed to determine the pre-
cise mechanism(s) of how SCs promote the survival andand integrated into spinal cord circuitry (e.g., forming
new oligodendrocytes and/or neurons) (19,41). How- differentiation of hESC-NPs.
Moreover, we found several unlabeled SCs in theever, to confirm this it needs to abolish human engrafted
cells by selective ablation with diphtheria toxin as deter- transplanted area, which suggest migration of endogenous
SCs to the injury site after SCI despite being part of themined previously (19). Our results are in agreement with
previous reports showing that transplanted NPs can sur- peripheral nervous system (PNS) (4,10,32). This result
shows that SC transplantation provides a microenviron-vive, migrate, and differentiate in vivo (13,33,67,70,85).
The secretion of trophic factors is another possible ment to increase neuronal differentiation of NPs and/or
FACING PAGE
Figure 6. The fate of hESC-NPs in the spinal cord. Representative figures related to cotransplanted hESC-NPs/SCs. Double
immunostaining using HNu, hESC-NPs marker, and mestin, a progenitor marker (A); TUJ1, β-III-tubulin intermediated neuronal
marker (B); MAP2, a mature neuron marker (C); GFAP, an astrocyte marker (D); myelin basic protein (MBP), a mature oligoden-
drocyte marker (E); and Ki67, a mitotic marker (F). Quantification of fate acquisition in hESC-NP and hESC-NP/SC groups (G).
To compare immunostaining data between hESC-NP and hESC-NP/SC groups, Student’s t-test was performed. a: p < 0.01. Scale
bars: 200 µm (A, B, D, E, F), 500 µm (C).
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